1. Home
  2. Detail

@carlafayyy:

carla
carla
Open In TikTok:
Region: DE
Friday 15 November 2024 14:39:55 GMT
39058
4439
13
730

Music

Download

No Watermark .mp4 (0.92MB) No Watermark(HD) .mp4 (1.45MB) Watermark .mp4 (0.97MB) Music .mp3

Comments

_54pt4
SAPTA :
idaman..🥰
2024-11-17 04:21:35
0
user298892298892
angellaaa :
😍😍😍
2024-11-15 15:34:04
3
pappoy049
JD :
😍😍
2024-11-15 15:58:35
1
ferbjir
Fer. :
@Oʀᴇᴏ 𝙆𝙞𝙡𝙇𝙚𝙍²³✔️ wolooooo
2024-11-30 13:34:35
1
isetsgpp1
isetz :
cantik banget kak
2024-11-29 02:01:58
0
reno.aditya_
Noiy.🐣 :
😁😁😁
2024-11-16 18:57:42
0
aldi_pasaribu17
aldi pasaribu :
komen ah
2024-11-16 13:04:40
0
eospaw
EoSPAW :
🥰
2024-11-16 12:32:52
0
akbarmaulafachreza
akbar maula fachreza :
🥰🥰
2024-11-16 12:28:01
0
cyaxpekz
celakaku :
tidurrr wee jngn ngebayangin yg ga pastii
2024-11-15 16:11:03
0
sujarwo14
sujarwo :
🥰🥰🥰🥰🥰🥰🥰🥰🥰
2024-11-15 15:03:49
0
star_12308
star *01* :
cantik 🥰🥰🥰🥰
2024-11-15 14:53:33
0
To see more videos from user @carlafayyy, please go to the Tikwm homepage.

Other Videos

The cutest baby ever omg ☺️☺️ #sportsphotography #fentysuperbrandday #photography #photographytips #womeninsports #baby #babygirl #babiesoftiktok #basketball #collegebasketball #basketballphotography #photography #sportsvideo
The cutest baby ever omg ☺️☺️ #sportsphotography #fentysuperbrandday #photography #photographytips #womeninsports #baby #babygirl #babiesoftiktok #basketball #collegebasketball #basketballphotography #photography #sportsvideo
she said “enough”✋🏽#tiktok #foryou Part 3-telling her another joke, posted!!! Contact licensing@newsflare.com to license
she said “enough”✋🏽#tiktok #foryou Part 3-telling her another joke, posted!!! Contact [email protected] to license
decretado esta #tpashow #risa #paratiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii #fyppppppppppppppppppppppp #🍑 #infielestiktok
decretado esta #tpashow #risa #paratiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii #fyppppppppppppppppppppppp #🍑 #infielestiktok
Quieren que les cuente cuanto me pagaron por mi primera campaña? #contentcreator #latinainfluencer
Quieren que les cuente cuanto me pagaron por mi primera campaña? #contentcreator #latinainfluencer
#parati insta Daimarrico😍
#parati insta Daimarrico😍
Two big study updates presented at ESMO on adjuvant ribociclib and abemaciclib (CDK 4/6 inhibitors) in early stage breast cancer. All explained in my Substack. Go to drteplinsky.substack.com. Bottom line if you just want the cliff notes: ⭐️ Ribociclib (Kisqali): At a median follow-up of 55.4 months, absolute improvement in invasive disease free survival (survival without disease) was 4.5% in patients receiving ribociclib (81% in endocrine therapy alone versus 85.5% in ribociclib+ET). ⭐️ Abemaciclib (Verzenio): 7 year overall survival was 86.8% with abemaciclib-ET and 85.0% with ET (absolute difference, 1.8%). This translates into a 15.8% lower risk of death with abemaciclib + endocrine therapy compared to endocrine therapy alone. Invasive disease free survival was improved by 6.5% at the 7 year mark with the addition of abemaciclib. Additionally, there is a significant difference in the numbers of patients who have developed a distant recurrence and are being treated for metastatic disease (there are 33% fewer patients living with metastatic disease: 180 vs 266 in the group treated with abemaciclib). Over time, this may lead to a further reduction in death from breast cancer. For all the details and nuanced info, check out the substack! @esmo_eur_oncology #esmo25 #cdk #breastcancer #kisqali #verzenio
Two big study updates presented at ESMO on adjuvant ribociclib and abemaciclib (CDK 4/6 inhibitors) in early stage breast cancer. All explained in my Substack. Go to drteplinsky.substack.com. Bottom line if you just want the cliff notes: ⭐️ Ribociclib (Kisqali): At a median follow-up of 55.4 months, absolute improvement in invasive disease free survival (survival without disease) was 4.5% in patients receiving ribociclib (81% in endocrine therapy alone versus 85.5% in ribociclib+ET). ⭐️ Abemaciclib (Verzenio): 7 year overall survival was 86.8% with abemaciclib-ET and 85.0% with ET (absolute difference, 1.8%). This translates into a 15.8% lower risk of death with abemaciclib + endocrine therapy compared to endocrine therapy alone. Invasive disease free survival was improved by 6.5% at the 7 year mark with the addition of abemaciclib. Additionally, there is a significant difference in the numbers of patients who have developed a distant recurrence and are being treated for metastatic disease (there are 33% fewer patients living with metastatic disease: 180 vs 266 in the group treated with abemaciclib). Over time, this may lead to a further reduction in death from breast cancer. For all the details and nuanced info, check out the substack! @esmo_eur_oncology #esmo25 #cdk #breastcancer #kisqali #verzenio

About

Legal